Lyndon Huang, Kassandra Corona, Kendall Wermine, Elvia Villarreal, Giovanna De La Tejera, Phillip Howard Keys, Alen Palackic, Amina El Ayadi, George Golovko, Steven E Wolf, Juquan Song
{"title":"非甾体抗炎药降低严重烧伤患者的凝血病发病率","authors":"Lyndon Huang, Kassandra Corona, Kendall Wermine, Elvia Villarreal, Giovanna De La Tejera, Phillip Howard Keys, Alen Palackic, Amina El Ayadi, George Golovko, Steven E Wolf, Juquan Song","doi":"10.3390/ebj5020009","DOIUrl":null,"url":null,"abstract":"<p><p>The study investigated the impact of nonsteroidal anti-inflammatory drugs (NSAIDs) on burn-induced coagulopathy in severely burned patients. Patients with a greater than 20% TBSA were identified in the TriNetX research network and categorized into receiving or not receiving NSAIDs in the first week after the burn. The statistical significance of the rate of burn-induced coagulopathy, mortality and sepsis in the week following injury was analysed. We observed 837 severely burned patients taking NSAIDS during the week following the burn and 1036 patients without. After matching for age, gender and race, the risk of burn-induced coagulopathy significantly decreased (<i>p</i> < 0.0001) in patients taking NSAIDs (17.7%) compared to those without (32.3%). Patients taking NSAIDs were also less likely to develop sepsis (<i>p</i> < 0.01) and thrombocytopenia (<i>p</i> < 0.001) or die the week following injury (<i>p</i> < 0.0001). In conclusion, the early protective effects of NSAIDs at reducing the risk of coagulopathy as well as sepsis and mortality occur during the acute phase of burns.</p>","PeriodicalId":72961,"journal":{"name":"European burn journal","volume":"5 2","pages":"104-115"},"PeriodicalIF":1.0000,"publicationDate":"2024-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11544790/pdf/","citationCount":"0","resultStr":"{\"title\":\"Nonsteroidal Anti-Inflammatory Drugs Decrease Coagulopathy Incidence in Severe Burn Patients.\",\"authors\":\"Lyndon Huang, Kassandra Corona, Kendall Wermine, Elvia Villarreal, Giovanna De La Tejera, Phillip Howard Keys, Alen Palackic, Amina El Ayadi, George Golovko, Steven E Wolf, Juquan Song\",\"doi\":\"10.3390/ebj5020009\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The study investigated the impact of nonsteroidal anti-inflammatory drugs (NSAIDs) on burn-induced coagulopathy in severely burned patients. Patients with a greater than 20% TBSA were identified in the TriNetX research network and categorized into receiving or not receiving NSAIDs in the first week after the burn. The statistical significance of the rate of burn-induced coagulopathy, mortality and sepsis in the week following injury was analysed. We observed 837 severely burned patients taking NSAIDS during the week following the burn and 1036 patients without. After matching for age, gender and race, the risk of burn-induced coagulopathy significantly decreased (<i>p</i> < 0.0001) in patients taking NSAIDs (17.7%) compared to those without (32.3%). Patients taking NSAIDs were also less likely to develop sepsis (<i>p</i> < 0.01) and thrombocytopenia (<i>p</i> < 0.001) or die the week following injury (<i>p</i> < 0.0001). In conclusion, the early protective effects of NSAIDs at reducing the risk of coagulopathy as well as sepsis and mortality occur during the acute phase of burns.</p>\",\"PeriodicalId\":72961,\"journal\":{\"name\":\"European burn journal\",\"volume\":\"5 2\",\"pages\":\"104-115\"},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2024-04-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11544790/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European burn journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3390/ebj5020009\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"CRITICAL CARE MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European burn journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/ebj5020009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
Nonsteroidal Anti-Inflammatory Drugs Decrease Coagulopathy Incidence in Severe Burn Patients.
The study investigated the impact of nonsteroidal anti-inflammatory drugs (NSAIDs) on burn-induced coagulopathy in severely burned patients. Patients with a greater than 20% TBSA were identified in the TriNetX research network and categorized into receiving or not receiving NSAIDs in the first week after the burn. The statistical significance of the rate of burn-induced coagulopathy, mortality and sepsis in the week following injury was analysed. We observed 837 severely burned patients taking NSAIDS during the week following the burn and 1036 patients without. After matching for age, gender and race, the risk of burn-induced coagulopathy significantly decreased (p < 0.0001) in patients taking NSAIDs (17.7%) compared to those without (32.3%). Patients taking NSAIDs were also less likely to develop sepsis (p < 0.01) and thrombocytopenia (p < 0.001) or die the week following injury (p < 0.0001). In conclusion, the early protective effects of NSAIDs at reducing the risk of coagulopathy as well as sepsis and mortality occur during the acute phase of burns.